20 articles
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-Ξ³/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Ficerafusp alfa plus pembrolizumab shows striking results in HPV-negative head and neck cancer, a notoriously difficult-to-treat population.
Researchers develop targeted drug that degrades FTO protein, disrupting ribosome production and protein synthesis in leukemia cells.
New review reveals why fecal microbiota transplants sometimes helpβand sometimes hurtβimmune checkpoint inhibitor cancer treatments.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Specific gut microbes produce compounds that reprogram fat cells to enhance immune responses against cancer.
Researchers developed rat and mouse models mimicking early and middle stages of oral submucous fibrosis using bleomycin injections.
Novel BRAF inhibitor mosperafenib demonstrates safety and efficacy in patients with advanced cancers, including those resistant to prior treatments.
Researchers find new therapeutic potential in existing medication for treating challenging desmoid tumors.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
New research reveals how gut microbiome restoration could treat inflammatory bowel disease and boost cancer treatments.
